GSK · Pharma and healthcare · one day
GSK (GSK): news on Saturday 7 November 2026
News from the 24 hours to Saturday morning, 7 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was dominated by GSK settling its COVID and RSV vaccine patent dispute with Moderna without payments, which removes a legal overhang. A Jemperli approval also helped, though softer vaccine sales, a rival hepatitis B readout and share price falls tempered the tone.
What drove it
- Moderna patent settlement
- Jemperli approval
- share price weakness
Around this day
8 stories · 17 headlines · strongest first
Pharma and healthcare on 7 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| Moderna and GSK resolve dispute over vaccine patents +6.86 headlines today · GSK and Moderna settled their COVID and RSV vaccine patent fight without payments. | ||
| +7.5 | Removes a patent dispute with no payments required | |
| +7.5 | Settlement covers both US and European disputes | |
| +7.3 | Major legal overhang settled across COVID and RSV products | |
| +7.3 | Repeat of the settlement news from a market data site | |
| +7.0 | Litigation in Delaware brought to a close | |
| +4.2 | Mainly about Moderna's results; GSK dispute resolution is a side benefit | |
| GSK valuation after Jemperli approval +4.43 headlines today · 4 in all, since 6 November · Pieces say GSK looks below fair value and note Q3 growth led by specialty medicines. | ||
| +5.8 | Regulatory approval for cancer drug and valuation upside | |
| +1.7 | Specialty growth offset by softer vaccine sales | |
| +1.7 | Specialty growth offset by softer vaccine sales | |
| GSK share price moves −0.42 headlines today · 8 in all, since 5 November · GSK shares fell over 2% amid selling pressure. | ||
| −4.2 | Share price drifting down on selling | |
| −4.2 | Shares dropped during the session on selling | |
| GSK sets out tentative dividend calendar for 2027 +0.52 headlines today · GSK published its provisional dividend schedule for 2027. | ||
| +0.5 | Routine dividend calendar notice | |
| +0.5 | Routine dividend calendar, nothing new on prospects | |
| Brii Bio hepatitis B trial result challenges GSK −3.31 headline today · In a Phase II study of hepatitis B, Brii Bio reported a 32% HBsAg loss. | ||
| −3.3 | Rival hepatitis B data challenges GSK's candidate | |
| GSK survey on respiratory virus disruption +1.31 headline today · A GSK survey found that 79% of adults who have chronic illnesses see their everyday routines disrupted by respiratory virus infections such as RSV. | ||
| +1.3 | Company-run survey supporting vaccine awareness | |
| Mansi Jamindar takes GSK's US lung oncology medical affairs leadership +0.81 headline today · Mansi Jamindar took on leadership of US lung oncology medical affairs at GSK. | ||
| +0.8 | Staff profile of an employee's new role; minor | |
| HP chooses GSK's Emma Walmsley as CEO 0.01 headline today · Fortune sets out why HP selected Emma Walmsley, who runs GSK, as its chief executive. | ||
| 0.0 | Former chief's new job elsewhere; little bearing on the company now | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.